A novel direct factor Xa inhibitory peptide with anti-platelet aggregation activity from Agkistrodon acutus venom hydrolysates

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chen, Meimei ^a   Ye, Xiaohui ^a   Ming, Xin ^b   Chen, Yahui ^a   Wang, Ying ^a   Su, Xingli ^a   Su, Wen ^a   Kong, Yi ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PEPTIDE; SNAKE VENOM;

AGKISTRODON; AMINO ACID SEQUENCE; ANIMAL; BLOOD CLOTTING TEST; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FEMALE; HYDROLYSIS; ISOLATION AND PURIFICATION; MALE; METABOLISM; MOLECULAR WEIGHT; MOUSE; RABBIT; RAT; THROMBOCYTE AGGREGATION; THROMBOSIS;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENOSINE DIPHOSPHATE; AGKISTRODON; AMINO ACID SEQUENCE; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION TESTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA INHIBITORS; FEMALE; HYDROLYSIS; MALE; MICE; MOLECULAR WEIGHT; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RABBITS; RATS; SNAKE VENOMS; THROMBOSIS;

EID: 84934880930     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10846     Document Type: Article

References (42)

1. Goto, S. & Tomita, A. Antithrombotic Therapy for Prevention of Various Thrombotic Diseases. Drug Dev. Res. 74, 568-574 (2013).
2. Jiang, L., Wang, Q., Shen, S., Xiao, T. & Li, Y. Discovery of glycyrrhetinic acid as an orally active, direct inhibitor of blood coagulation factor Xa. Thromb. Res. 133, 501-506 (2014).
3. Al-Obeidi, F. & Ostrem, J. A. Factor Xa inhibitors by classical and combinatorial chemistry. Drug Discovery Today 3, 223-231 (1998).
4. Philippides, G. J. & Loscalzo, J. Potential advantages of direct-acting thrombin inhibitors. Coron. Artery Dis. 7, 497-507 (1996).
5. Antman, E. M. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 90, 1624-1630 (1994).
6. Neuhaus, K. et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 90, 1638-1642 (1994).
7. Vlasuk, G. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb. Haemost. 70, 212-216 (1993).
8. Esmon, C. T. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb. Haemost. 111, 625-633 (2014).
9. Neeper, M. et al. Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa. J. Biol. Chem. 265, 17746-17752 (1990).
10. Schaffer, L. W., Davidson, J. T., Vlasuk, G. P., Dunwiddie, C. T. & Siegl, P. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Arterioscler. Thromb. Vasc. Biol. 12, 879-885 (1992).
11. Lynch, J. J. et al. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc. Res. 28, 78-85 (1994).
12. Lee, S.-H., Qian, Z.-J. & Kim, S.-K. A novel angiotensin I converting enzyme inhibitory peptide from tuna frame protein hydrolysate and its antihypertensive effect in spontaneously hypertensive rats. Food Chem. 118, 96-102 (2010).
13. Ren, J. et al. Purification and identification of antioxidant peptides from grass carp muscle hydrolysates by consecutive chromatography and electrospray ionization-mass spectrometry. Food Chem. 108, 727-736 (2008).
14. Tang, W., Zhang, H., Wang, L. & Qian, H. Membrane-disruptive property of a novel antimicrobial peptide from anchovy (Engraulis japonicus) hydrolysate. Int. J. Food Sci. Tech. 49, 969-975 (2014).
15. Ren, Y. et al. Isolation and identification of a novel anticoagulant peptide from enzymatic hydrolysates of scorpion (Buthus martensii Karsch) protein. Food Res. Int. 64, 931-938 (2014).
16. Nasri, R. et al. Anticoagulant activities of goby muscle protein hydrolysates. Food Chem. 133, 835-841 (2012).
17. Hutton, R. & Warrell, D. Action of snake venom components on the haemostatic system. Blood Rev. 7, 176-189 (1993).
18. Li, S., Ji, H., Cheng, X., Li, B. X. & Ng, T. Antithrombotic and thrombolytic activities of Agkisacutacin, a snake venom proteinase, in experimental models. Gen. Pharmacol : Vasc. S. 35, 179-187 (2000).
19. Zhu, Z., Gong, W., Zhu, X., Teng, M. & Niu, L. Purification, characterization and conformational analysis of a haemorrhagin from the venom of Agkistrodon acutus. Toxicon 35, 283-292 (1997).
20. Xiong, J. et al. New peptide pENW (pGlu-Asn-Trp) inhibits platelet activation by attenuating Akt phosphorylation. Eur. J. Pharm. Sci. 45, 552-558 (2012).
21. Jiang, D. et al. Ac-AP-12, a novel factor Xa anticoagulant peptide from the esophageal glands of adult Ancylostoma caninum. Mol. Biochem. Parasitol. 177, 42-48 (2011).
22. Thakur, R. et al. A new peptide (Ruviprase) purified from the venom of Daboia russelii russelii shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor Xa. Biochimie 105, 149-158 (2014).
23. Waxman, L., Smith, D. E., Arcuri, K. E. & Vlasuk, G. P. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 248, 593-596 (1990).
24. Graff, J. & Harder, S. Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment. Clin. Pharmacokinet. 52, 243-254 (2013).
25. Gan, W. et al. An anticoagulant peptide from the human hookworm, Ancylostoma duodenale that inhibits coagulation factors Xa and XIa. FEBS Lett. 583, 1976-1980 (2009).
26. Yang, Y. et al. Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. Heart 92, 1131-1137 (2006).
27. Koster, A. et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J. Thorac. Cardiov. Sur. 122, 1254-1255 (2001).
28. Sabatine, M. S., Tu, T. M. & Jang, I.-K. Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase. J. Thromb. Thrombolysis 10, 189-196 (2000).
29. Silver, M. J., Hoch, W., Kocsis, J. J., Ingerman, C. M. & Smith, J. B. Arachidonic acid causes sudden death in rabbits. Science 183, 1085-1087 (1974).
30. Peters, R. et al. The characterisation of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Thromb. Haemost. 65, 268-274 (1991).
31. Kawamura, M. et al. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban. J. Pharmacol. Exp. Ther. 277, 502-510 (1996).
32. Chuang, Y.-J., Swanson, R., Raja, S. M. & Olson, S. T. Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence evidencr for an exosite determinsnt of factor Xa specificity in heparinactivated antithrombin. J. Biol. Chem. 276, 14961-14971 (2001).
33. Wong, P. C. et al. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. J. Thromb. Thrombolysis 24, 43-51 (2007).
34. Konishi, N., Hiroe, K. & Kawamura, M. Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats. Thromb. Res. 126, 124-129 (2010).
35. Wong, P., Watson, C. & Crain, E. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J. Thromb. Haemost. 6, 1736-1741 (2008).
36. Chu, V. et al. In vitro characterization of a novel factor Xa inhibitor, RPR 130737. Thromb. Res. 99, 71-82 (2000).
37. Kong, Y. et al. A novel peptide inhibitor of platelet aggregation from stiff silkworm, Bombyx batryticatus. Peptides 53, 70-78 (2014).
38. King, J. B., West, M. B., Cook, P. F. & Hanigan, M. H. A novel, species-specific class of uncompetitive inhibitors of γ -glutamyl transpeptidase. J. Biol. Chem. 284, 9059-9065 (2009).
39. Sperzel, M. & Huetter, J. Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J. Thromb. Haemost. 5, 2113-2118 (2007).
40. Umar, A. et al. Effects of armagnac extracts on human platelet function in vitro and on rat arteriovenous shunt thrombosis in vivo. Thromb. Res. 110, 135-140 (2003).
41. Umar, A. et al. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. Fundam. Clin. Pharmacol. 18, 559-563 (2004).
42. Xiong, J. et al. Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp). J. Pharm. Pharmacol. 61, 89-94 (2009).